On this page
Women's health items on the FNP boards combine screening grades, STI treatment, contraceptive eligibility and pregnancy prevention. Most can be answered by matching the patient to the right row of a published table. The 12 questions below drill those tables.
They are written for candidates using FNP-C exam prep, which follows the NPCB (formerly AANPCB) FNP blueprint. Prenatal content is counted inside the adolescent, young adult and middle adult groups on that blueprint; see the AANP FNP exam blueprint guide.
This set is exam practice written from the USPSTF, CDC, AAP and FDA label sources listed under References. The questions are original PrepSolution items, not NPCB or ANCC exam questions. It is not clinical guidance for any patient, and it has not been reviewed by a credentialed nurse practitioner.
Screening
Question 1: Mammography start age
A 42-year-old at average risk asks when to start mammograms. What does the 2024 USPSTF recommendation say?
- A. Start at 50, every 2 years
- B. Annual mammography from 40
- C. Biennial screening mammography from 40 to 74
- D. Start at 45, annually
Best answer: C. USPSTF (2024) recommends biennial screening mammography for women aged 40 to 74. Grade B. This replaced the earlier recommendation to start routine screening at 50.
- A is not the best answer. The 2024 update lowered the start age to 40.
- B is not the best answer. USPSTF recommends every 2 years, not annually.
- D is not the best answer. Neither 45 nor annual screening is the USPSTF recommendation.
Question 2: Mammography after 75
A healthy 77-year-old asks whether to continue screening mammography. What does USPSTF conclude?
- A. Evidence is insufficient to assess benefits and harms (I statement)
- B. Continue every 2 years (Grade B)
- C. Stop; recommends against (Grade D)
- D. Switch to annual screening
Best answer: A. For women 75 or older, USPSTF concludes the current evidence is insufficient to assess the balance of benefits and harms of screening mammography.
- B is not the best answer. The B recommendation covers ages 40 to 74.
- C is not the best answer. USPSTF does not recommend against it; it is an I statement.
- D is not the best answer. Annual screening is not recommended at any age.
Question 3: Bone density before 65
A 58-year-old postmenopausal woman has a parental history of hip fracture. What does the 2025 USPSTF recommendation say about osteoporosis screening?
- A. Wait until 65
- B. Screening is not recommended for women
- C. Evidence is insufficient
- D. Screen, because she is postmenopausal and under 65 with a risk factor
Best answer: D. USPSTF (2025) recommends screening for osteoporosis in women 65 or older and in postmenopausal women younger than 65 who are at increased risk. Grade B.
- A is not the best answer. Increased risk moves screening earlier than 65.
- B is not the best answer. USPSTF recommends screening for women in both groups.
- C is not the best answer. Both groups have a B grade.
Question 4: Chlamydia screening
A sexually active 22-year-old with one partner and no symptoms is seen for contraception. What does USPSTF recommend about chlamydia?
- A. Screen only if symptomatic
- B. Screen all sexually active women 24 and younger
- C. Screen only with more than one partner
- D. Screen only during pregnancy
Best answer: B. USPSTF recommends screening for chlamydia in all sexually active women 24 or younger, and in women 25 or older at increased risk. Grade B. The same applies to gonorrhea.
- A is not the best answer. Screening is for asymptomatic women.
- C is not the best answer. Age 24 or younger is enough; extra risk factors are needed only from 25.
- D is not the best answer. The recommendation includes but is not limited to pregnant persons.
Pregnancy
Question 5: Gestational diabetes timing
When does USPSTF recommend screening asymptomatic pregnant persons for gestational diabetes?
- A. At the first prenatal visit for everyone
- B. Only at 36 weeks
- C. Only if glycosuria is found
- D. At 24 weeks of gestation or after
Best answer: D. USPSTF recommends screening for gestational diabetes in asymptomatic pregnant persons at 24 weeks of gestation or after. Grade B. Screening before 24 weeks has an I statement.
- A is not the best answer. Universal screening before 24 weeks is not the B recommendation.
- B is not the best answer. Screening is at 24 weeks or after, not delayed to 36.
- C is not the best answer. Screening does not depend on glycosuria.
Question 6: Aspirin to prevent preeclampsia
A pregnant person at high risk for preeclampsia asks about aspirin. What does USPSTF recommend?
- A. Avoid aspirin in pregnancy
- B. Full-dose aspirin from conception
- C. Low-dose aspirin (81 mg/day) after 12 weeks of gestation
- D. Aspirin only after 36 weeks
Best answer: C. USPSTF recommends low-dose aspirin (81 mg/day) as preventive medication after 12 weeks of gestation in persons at high risk for preeclampsia. Grade B.
- A is not the best answer. USPSTF recommends it for high-risk pregnancies.
- B is not the best answer. The dose is low and the start is after 12 weeks.
- D is not the best answer. The recommendation begins after 12 weeks, not at 36.
Question 7: Hormone therapy for prevention
A 56-year-old with no menopausal symptoms asks to start estrogen plus progestin to prevent heart disease and osteoporosis. What does USPSTF recommend?
- A. Recommend it for women under 60
- B. Recommend against combined estrogen and progestin for primary prevention of chronic conditions
- C. Recommend it if bone density is low
- D. Evidence is insufficient
Best answer: B. USPSTF recommends against using combined estrogen and progestin for the primary prevention of chronic conditions in postmenopausal persons. Grade D. The recommendation is about prevention, not treatment of menopausal symptoms.
- A is not the best answer. USPSTF does not recommend it for prevention at any age.
- C is not the best answer. Low bone density does not change the prevention recommendation.
- D is not the best answer. This is a D recommendation, not an I statement.
Sexually transmitted infections
Question 8: Treating chlamydia
A nonpregnant 20-year-old tests positive for chlamydia and has no allergies. Which regimen does CDC list as recommended?
- A. Doxycycline 100 mg orally twice a day for 7 days
- B. Azithromycin 1 g orally once
- C. Ceftriaxone 500 mg IM once
- D. Metronidazole 500 mg orally twice a day for 7 days
Best answer: A. The CDC 2021 STI Treatment Guidelines list doxycycline 100 mg orally twice a day for 7 days as the recommended regimen for chlamydial infection in adolescents and adults. Azithromycin 1 g once is an alternative.
- B is not the best answer. CDC lists azithromycin as an alternative, not the recommended regimen.
- C is not the best answer. Ceftriaxone treats gonorrhea, not chlamydia.
- D is not the best answer. Metronidazole is a bacterial vaginosis regimen.
Question 9: Treating gonorrhea
A 24-year-old weighing 68 kg has uncomplicated cervical gonorrhea. Chlamydia testing is pending. What does CDC recommend?
- A. Ceftriaxone 250 mg IM once with azithromycin 1 g
- B. Doxycycline alone
- C. Ciprofloxacin 500 mg once
- D. Ceftriaxone 500 mg IM once, plus doxycycline 100 mg twice a day for 7 days because chlamydia has not been excluded
Best answer: D. CDC recommends ceftriaxone 500 mg IM in a single dose for persons under 150 kg with uncomplicated gonorrhea of the cervix, urethra or rectum, and, if chlamydia has not been excluded, treatment for chlamydia with doxycycline 100 mg twice a day for 7 days.
- A is not the best answer. This was an older regimen; the 2021 guideline uses 500 mg and doxycycline for chlamydia.
- B is not the best answer. Doxycycline alone does not treat gonorrhea.
- C is not the best answer. Ciprofloxacin is not the CDC recommended regimen for gonorrhea.
Contraception
Question 10: Migraine and the pill
A 27-year-old with migraine with aura asks for a combined oral contraceptive. How does CDC's U.S. MEC classify combined hormonal contraception for her?
- A. Category 1: no restriction
- B. Category 2: advantages generally outweigh risks
- C. Category 4: unacceptable health risk
- D. Category 3: risks usually outweigh advantages
Best answer: C. U.S. MEC classifies combined hormonal contraceptives as category 4 for migraine with aura. Migraine without aura is category 2.
- A is not the best answer. Category 1 is for conditions with no restriction.
- B is not the best answer. Category 2 applies to migraine without aura.
- D is not the best answer. Migraine with aura is category 4, not 3.
Question 11: Smoking and age
A 38-year-old smokes 20 cigarettes a day and asks to continue her combined pill. What is the U.S. MEC category for combined hormonal contraception?
- A. Category 4
- B. Category 2
- C. Category 3
- D. Category 1
Best answer: A. U.S. MEC rates combined hormonal contraception for smokers as category 2 under age 35; at 35 or older it is category 3 for fewer than 15 cigarettes a day and category 4 for 15 or more. At 38 smoking 20 a day she is category 4.
- B is not the best answer. Category 2 applies to smokers under 35.
- C is not the best answer. Category 3 applies at 35 or older with fewer than 15 cigarettes a day.
- D is not the best answer. Category 1 does not apply to smokers 35 or older.
Question 12: Depot medroxyprogesterone and bone
An 18-year-old has used depot medroxyprogesterone for 2 years and wants to continue. What does the boxed warning say?
- A. Bone loss is fully reversible, so duration does not matter
- B. It may cause significant bone mineral density loss, and it is not recommended as a long-term method (longer than 2 years) unless other options are inadequate
- C. It is contraindicated after age 18
- D. Calcium supplements remove the risk
Best answer: B. The boxed warning says users may lose significant bone mineral density, that loss increases with duration and may not be completely reversible, and that it is not recommended as a long-term (longer than 2 years) method unless other options are considered inadequate.
- A is not the best answer. The label says bone loss may not be completely reversible.
- C is not the best answer. The label has no age-18 contraindication.
- D is not the best answer. The label does not say supplements remove the risk.
Tables to know
| Topic | Population | Grade |
|---|---|---|
| Mammography every 2 years | Women 40 to 74 | B |
| Mammography | Women 75 and older | I |
| Osteoporosis screening | Women 65 and older; postmenopausal under 65 at increased risk | B |
| Chlamydia and gonorrhea screening | Sexually active women 24 and younger; older if at increased risk | B |
| Gestational diabetes screening | Pregnant, 24 weeks or later | B |
| Low-dose aspirin | Pregnant, high risk for preeclampsia, after 12 weeks | B |
| Estrogen plus progestin for prevention | Postmenopausal | D |
| Condition | Category |
|---|---|
| Migraine without aura | 2 |
| Migraine with aura | 4 |
| Smoker under 35 | 2 |
| Smoker 35 or older, fewer than 15 a day | 3 |
| Smoker 35 or older, 15 or more a day | 4 |
| Breastfeeding, under 21 days postpartum | 4 |
How should you use this set?
Match the patient to the right row before you read the options: age, pregnancy status, smoking, aura. For STI regimens, the CDC 2021 guidelines are the reference the exam expects. For practice across the full blueprint, see FNP-C exam prep, and for the companion sets, the FNP cardiovascular practice questions and FNP pediatrics practice questions.
References
- [1] USPSTF (2024). Breast Cancer: Screening. USPSTF. USPSTF
- [2] USPSTF (2025). Osteoporosis to Prevent Fractures: Screening. USPSTF. USPSTF
- [3] USPSTF (2021). Chlamydia and Gonorrhea: Screening. USPSTF. USPSTF
- [4] USPSTF (2021). Gestational Diabetes: Screening. USPSTF. USPSTF
- [5] USPSTF (2021). Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality. USPSTF. USPSTF
- [6] USPSTF (2022). Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Persons. USPSTF. USPSTF
- [7] FDA label (2026). Medroxyprogesterone acetate injectable suspension. FDA label. FDA label
- [8] CDC (2021). Sexually Transmitted Infections Treatment Guidelines, 2021, Chlamydial Infections. CDC. CDC
- [9] CDC (2021). Sexually Transmitted Infections Treatment Guidelines, 2021, Gonococcal Infections Among Adolescents and Adults. CDC. CDC
- [10] CDC (2024). U.S. Medical Eligibility Criteria for Contraceptive Use, Combined Hormonal Contraceptives. CDC. CDC
Help us improve this guide
How helpful was this article?
One tap helps us understand what’s useful.
Frequently asked questions
The 2024 recommendation is biennial screening mammography from 40 to 74.
CDC's 2021 STI Treatment Guidelines recommend doxycycline 100 mg orally twice a day for 7 days for adolescents and adults; azithromycin 1 g once is an alternative.
Ceftriaxone 500 mg IM once for persons under 150 kg, plus chlamydia treatment with doxycycline if chlamydia has not been excluded.
U.S. MEC classifies combined hormonal contraception as category 4 (unacceptable health risk) for migraine with aura.
Only where the source states the exact dose, as CDC does for STI regimens and USPSTF does for low-dose aspirin. Doses are quoted, not calculated.
No. They are original PrepSolution practice items written from the USPSTF, CDC and FDA label sources listed under References. They have not been reviewed by a credentialed nurse practitioner and are not clinical guidance.
Keep practicing for the FNP-C.
Review the study tools, access options and price, or start with free practice.
Related Articles
FNP Pediatrics Practice Questions: 12 With Rationales
Twelve original FNP pediatrics questions on USPSTF screening grades, newborn and infant prevention, strep testing, lead and vaccine timing, each keyed to a named source.
FNP Pharmacology Practice Questions: Boxed Warnings and Label Rules
Eleven original FNP pharmacology questions on contraindications, boxed warnings and administration rules for common primary-care drugs, each keyed to the FDA label.
AANP FNP Exam Blueprint: Domains, Age Groups and Question Counts
The AANP FNP exam has 135 scored questions split across four domains and eight age groups. See every count from the 2024 blueprint, the tasks under each domain, and what the blueprint leaves out.
